The World Health Organization agrees to the binding endeavor treating legally

The World Health Organization (WHO) has approved the text of a binding treaty law designed to better address future epidemics.

The agreement aims to avoid not organizing and competing for the resources that were seen during the Covid-19 outbreak.

The main elements include rapid data participation on new diseases, to ensure that scientists and pharmaceutical companies can work more quickly to develop treatments and vaccines.

For the first time, those who himself also have an overview of global supply chains of masks, medical dresses and other PPE.

The Director General of the World Health Organization, Dr. Tedros Adwanum Guerber, described the deal as a “milestone on our common journey towards a safer world.”

He said, “(Member States) has also proven that multiple parties alive and in good health, and that in our divided world, countries are still working together to find a common ground and a common response to common threats.”

The binding agreement came legally early on Wednesday after three years of talks between member states.

This is only the second time in the history of the World Health Organization that is 75 years old, an international agreement of this type-the first is the tobacco control deal in 2003.

It is still officially adopted by members when they meet with the World Health Society next month.

American negotiators were not part of the final discussions after President Donald Trump announced his decision to withdraw from the World Health Agency, and the United States will not be binding on the agreement when it left in 2026.

Under the agreed conditions, countries will ensure that the drug -related drugs are available around the world in the outbreak of the future.

Participating manufacturers will have to allocate 20 % of their production of vaccines, treatments and diagnoses to the World Health Organization. At least 10 % with the REST provided at reasonable prices.

The two countries have also agreed to transfer health techniques to poor countries as long as they are mutually agreed.

This would enable more local production of vaccines and medications during the epidemic, but the item was very controversial.

Developing countries are still angry at the way in which wealthy countries bought vaccines and biopsy during Covid-19, while countries with large pharmaceutical industries are concerned that compulsory conversions may undermine research and development.

At the core of the agreement, there is a proposed system to reach pathogens and the participation of benefits (PABS), which allows the exchange of the fastest data between pharmaceutical companies.

This enables these companies to start working on new medications more quickly at any outbreak in the future.